Poseida Therapeutics Inc
NASDAQ:PSTX
Intrinsic Value
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies an... [ Read More ]
The intrinsic value of one PSTX stock under the Base Case scenario is 2.37 USD. Compared to the current market price of 2.02 USD, Poseida Therapeutics Inc is Undervalued by 15%.
Valuation Backtest
Poseida Therapeutics Inc
Run backtest to discover the historical profit from buying and selling PSTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Poseida Therapeutics Inc
Current Assets | 226.5m |
Cash & Short-Term Investments | 212.2m |
Receivables | 9m |
Other Current Assets | 5.3m |
Non-Current Assets | 47.4m |
PP&E | 40.8m |
Intangibles | 5.5m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 71.3m |
Accounts Payable | 3.3m |
Accrued Liabilities | 33.6m |
Other Current Liabilities | 34.4m |
Non-Current Liabilities | 98.9m |
Long-Term Debt | 58.6m |
Other Non-Current Liabilities | 40.3m |
Earnings Waterfall
Poseida Therapeutics Inc
Revenue
|
64.7m
USD
|
Operating Expenses
|
-194.2m
USD
|
Operating Income
|
-129.5m
USD
|
Other Expenses
|
6.1m
USD
|
Net Income
|
-123.4m
USD
|
Free Cash Flow Analysis
Poseida Therapeutics Inc
What is Free Cash Flow?
PSTX Profitability Score
Profitability Due Diligence
Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
PSTX Solvency Score
Solvency Due Diligence
Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PSTX Price Targets Summary
Poseida Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for PSTX is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.
Ownership
PSTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PSTX Price
Poseida Therapeutics Inc
Average Annual Return | -27.38% |
Standard Deviation of Annual Returns | 9.04% |
Max Drawdown | -90% |
Market Capitalization | 193.2m USD |
Shares Outstanding | 96 490 000 |
Percentage of Shares Shorted | 5.76% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).
Contact
IPO
Employees
Officers
The intrinsic value of one PSTX stock under the Base Case scenario is 2.37 USD.
Compared to the current market price of 2.02 USD, Poseida Therapeutics Inc is Undervalued by 15%.